NHS Framework for the NHS London Region, Branded Medicines — Tranche A plus Cytokine Modulators and Other Products and Dolutegravir/Lamivudine

Descriptions

NHS framework for the NHS London Region, Branded Medicines — Tranche A, Annual Tranche — Cytokine Modulators and other products and Dolutegravir/Lamivudine. Offer reference number: CM/PHR/16/5516 CM/PHR/16/5516/01 — London Tranche A — 1 September 2020 to 31 August 2022 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/16/5516/02 — London Annual Tranche — Cytokine Modulators and other products — 1 September 2020 to 31 August 2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months. CM/PHR/16/5516/03 — NHS framework agreement for the supply of Dolutegravir/Lamivudine — North of England — 1 September 2020-28 February 2021, South of England — 1 September 2020-31 August 2021, Midlands and East — 1 September 2020-28 February 2022, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.